Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-09-12
1998-02-24
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514485, A01N 4302
Patent
active
057212708
ABSTRACT:
A method of inhibiting human IL-5 gene transcription, mRNA expression and protein production by human T-cells using one or more compounds selected from those shown by formula I shown below (where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group) and a therapeutic agent for allergic and eosinophilic inflammatory diseases which contains one or more compounds selected from those shown by the formula. ##STR1##
REFERENCES:
patent: 4843092 (1989-06-01), Shichi et al.
Mori et al., "Allergen-Specific Human T Cell Clones Produce Interleukin-5 upon Stimulation with the Th1 Cytokine Interleukin-2", International Archives of Allergy and Immunology (1995) 107:220-222.
Sheffer, "International Consensus Report on the Diagnosis and Management of Asthma", Clinical and Environmental Allergy Report, May 1992, vol. 22, Supp. 1, pp. 1-72.
Okudaira et al., "Enhanced Production and Gene Expression of IL-5 in Bronchial Asthma", Allergy and Clinical Immunology News (1994) 19-25.
Mori et al., "Regulation of Interleukin-5 Production by Peripheral Blood Mononuclear Cells from Atopic Patients with FK506, Cyclosporin A and Glucocorticoid", International Archives Allergy and Immunology (1994) 104(suppl 1):32-35.
Lopez et al., "Recombinant Human Interleukin 5 is a Selective Activator of Human Eosinophil Function", Journal of Experimental Medicine (1988) 167:219-224.
Egan et al., "Inhibition of Pulmonary Eosinophilia and Hyperactivity by Antibodies to Interleukin-5", International Archives Allergy and Immunology (1995) 107:321-322.
Mori et al., "IL-5 Production CD4+ T Cells of Asthmatic Patients is Suppressed by Glucocorticoids and the Immunosuppressants FK506 and Cyclosporin A", International Immunology (1995) 7(3):449-457.
Mori et al., "Atopic Diseases and Eosinophilic Inflammation-Possible Management with Agents Which Downregulate IL-5 Gene Transcription", Environmental Dermatology (1994) 1:42-54.
Callewaert et al., "Tetranactin, a Macrotetrolide Antibiotic, Suppresses in vitro Proliferation of Human Lymphocytes and Generation of Cytotoxicity", Immunopharmacology (1988) 16:25-32.
Tanouchi et al., "Immunosuppressive Effects of Polynactins (Tetranactin, Trinactin and Dinactin) on Experimental Autoimmune Uveoretinitis in Rats", Jpn. J. Ophthalmol. (1987) 31:218-229.
Tanouchi et al., "Immunosuppressive and Anti-Proliferative Effects of a Macrotetroide Antibiotic Tetranactin", Immunology (1988) 63:471-475.
Mori Akio
Okudaira Hirokazu
Environmental Research Institute, Inc.
Richter Johann
Sackey Ebenezer
LandOfFree
Drugs for allergic and eosinophilic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drugs for allergic and eosinophilic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drugs for allergic and eosinophilic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1875602